A B S T R A C T To determine whether hydralazine, a systemic vasodilator, exerted a similar effect on the pulmonary circulation, we studied the circulatory changes in dogs during three interventions: (a ) the control state during room air ventilation; (b) during continuous hypoxic ventilation with 10% oxygen, and maintaining continuous hypoxic ventilation; and (c) after 1 mg/kg hydralazine intravenously.
INTRODUCTION
Prostaglandins are metabolites of arachidonic acid which exert a variety of effects on platelet function and vascular smooth muscle in various animal species (1).
In the lung, prostaglandins F2ca (2, 3) and E2 (4) have been demonstrated to cause vasoconstriction, but prostaglandins El (5, 6) and I2 (prostacyclin) (7-9) promote vasodilatation. However, the contribution of these prostaglandins to the modulation of the pulmonary circulation in normal anid disease states has not been clearly defined (10) (11) (12) (13) (14) (15) (16) (17) .
The prostaglandin system has also been linked to the pharmacologic actions of several drugs that have effects on the cardiovascular system, including nitroglycerin (18) , propranolol (19) , and furosemide (20) . Hydralazine is a vasodilator whose antihypertensive effect may also be mediated by prostaglandins (21) (22) (23) . In addition to its systemic effects, hydralazine has recently been demonstrated to lower pulmonary arteriolar resistance in patients with pulmonary hypertension secondary to hypoxic lung disease (24) , and in patients with idiopathic pulmonary hypertension (25) . Ifhydralazine has a pulmonary vasodilatory effect, it is possible that this effect is mediated by prostaglandins. This study evaluates the hemodynamic effects of hydralazine in the setting of acute, hypoxic pulmonary hypertension and examines the influence of the administration of inhibitors of prostaglandin synthesis on the hemodynamic effects of hydralazine. and intubated with a cuffed endotracheal tube. The animals were ventilated with room air, using an animal respirator (Harvard Apparatus Co., S. Natick, Mass.) to regulate the minute ventilation so that the arterial Pco2 and pH were maintained within the normal range. A polyethylene catheter was inserted into a femoral artery, and a second catheter was inserted into a peripheral limb vein for the administration of drugs. A balloon-tipped flotation catheter was inserted into a femoral vein and advanced under fluoroscopic guidance to a brance of either main pulmonary artery. Pulmonary artery, pulmonary arterial wedge, and femoral artery pressures were measured using Statham PR231D and PR23AC pressure transducers (Statham Instruments, Inc., Oxnard, Calif.), respectively, and the pressure tracings were continuously displayed on a physiologic recorder (Electronics for Medicine, Inc., Pleasantville, N. Y.). Heart rate was measured from a lead II electrocardiogram. Airway pressure was monitored by a manometer connected to the endotracheal tube. Timed collections of minute ventilation were measured in a Tissot gasometer and their oxygen content was analyzed using a Beckman gas analyzer (Beckman Instruments, Inc., Fullerton, Calif.). From this data, total body oxygen consumption was determined, corrected to STPD. Arterial and mixed venous blood samples were collected anaerobically in heparinized syringes, and Po2, Pco2, pH, total hemoglobin, and oxyhemoglobin contents were measured using an IL 213 blood gas analyzer and IL 182 Co-oximeter (Instrumentation Laboratory, Inc., Lexington, Mass.). Cardiac output was then calculated from this data using the Fick equation. Pulmonary arteriolar resistance, defined as the mean pulmonary artery pressure minus the pulmonary artery wedge pressure (millimeters Hg) divided by the cardiac output (liters per minute), is reported in units.
After 30 min of room air ventilation, hemodynamic parameters were measured (control group), and continuous ventilation with a gas mixture consisting of 10% oxygen and 90% nitrogen was begun. Pentobarbital sodium (3-5 mg/kg i.v.) was given periodically as needed to maintain the level of anesthesia. After 1 h of continuous hypoxic ventilation, we repeated the hemodynamic studies (hypoxia group), and then injected hydralazine 0.5, 1.0, or 1.5 mg/kg through the peripheral venous line. We monitored continuously the systemic and pulmonary arterial pressures and repeated the measurements 60 min after the injection of hydralazine (hypoxia plus hydralazine group).
A separate group of dogs received subcutaneous injections of either indomethacin or meclofenamate, 5 mg/kg, twice daily for 2 d. The final dose ofeither cyclo-oxygenase inhibitor was given 2 h before study. Indomethacin and meclofenamate were dissolved in a 2 M excess of sodium carbonate, and neutral phosphate buffer was added to bring each dose to a total volume of 1 ml. Previous experience has documented that prostaglandin synthesis is effectively inhibited by this dosage in several species (18, (26) (27) (28) (29) (30) . The pretreated animals underwent identical study, receiving hydralazine 1 mg/kg i.v. after 1 h of continuous hypoxic ventilation.
To determine the influence of indomethacin on the effects of a known vasodilator, three dogs were pretreated with indomethacin 5 mg/kg s.c. twice daily for 2 d, and after 1 h of continuous hypoxic ventilation, received an infusion of prostacyclin 5 ,ug/kg per min into a peripheral limb vein for 2 min. Prostacyclin was stored in absolute ethanol at -700C. Immediately before use, the ethanol was evaporated under a stream of nitrogen, and prostacyclin was dissolved in sterile physiologic saline. Pulmonary and systemic arterial pressures were recorded at 2, 7, 10, 15, and 20 min.
The data are presented as the mean±SEM. Statistical analysis was performed by one-way analysis ofvariance followed by a multiple range test when the F value indicated significant differences among group means, and by the t test for paired data to compare the data from the two groups (31). . 1 shows the effects of continuous hypoxic ventilation on the hemodynamics of a group of five untreated dogs. The increases in mean pulmonary arterial pressure and pulmonary arteriolar resistance during continuous hypoxic ventilation remained stable for a 3-h period. Mean aortic pressure, cardiac output, and pulmonary arterial wedge pressure were unchanged compared with base-line room air levels.
RESULTS

Fig
The data during room air ventilation reflect normal base-line hemodynamics in the group receiving no pretreatment and the group pretreated with indomethacin (Tables I and II) . The pulmonary artery pressures were identical (10.0+1.2 vs. 10.6+ 1.2 mm Hg, NS), as were the pulmonary artery wedge pressures and the mean heart rate. The pulmonary arteriolar resistance was slightly higher in the indomethacin-pretreated group (1.51+0.19 vs. 2.50+0.48 U), and the mean femoral artery pressure was higher in the indomethacin-pretreated group (145.7+6.5 vs. 153.0+9.7 mm Hg), but these differences were not statistically significant. The total systemic resistance was significantly higher in the indomethacin-pretreated group (43.7+3.2 vs. 58.6±6.9 U, P < 0.05).
Ventilation with 10% oxygen induced significant and equivalent elevations of pulmonary arterial pressure in both groups (Table III) . Systemic arterial pressure, pulmonary arterial wedge pressure, and heart rate were not changed. Cardiac output decreased slightly in both groups. The levels of pulmonary artery pressure remained stable during the period ofhypoxic ventilation, and the arterial pH and Pco2 were equivalent in both groups. The arterial Po2 ranged between 35 and 45 torr in all the animals during this phase of the study.
The intravenous injection of hydralazine 1 mg/kg resulted in a significant fall in the pulmonary artery pressure in the nonpretreated group. This response was apparent within 20 min after the injection, and persisted for 1.5-2 h. The pulmonary arteriolar resistance was lowered as well, but it remained slightly higher than the control value. Cardiac output, pulmonary artery wedge pressure, heart rate, and arteriovenous oxygen difference were not affected by hydralazine. Mean systemic pressure was lowered by hydralazine, but this was not statistically significant.
The dose-response relationships with hydralazine are shown in Fig. 2 . The dogs receiving hydralazine 0.5 mg/kg evinced minimal pulmonary or systemic vasodilatation. At doses of 1.0 and 1.5 mg/kg more pronounced pulmonary vasodilatation was seen, accompanied by modest decreases in systemic arterial pressure.
In contrast to the responses observed in the animals receiving no pretreatment, the dogs that had been pretreated with indomethacin evinced no change in either pulmonary artery pressure or pulmonary arteriolar re- (Fig. 3) . Systemic arterial presTo exclude the possibility that the blockade of the sure fell slightly in this group, but there were no signifi-pulmonary effects of hydralazine may be due to an cant changes in any of the hemodynamic variables after action ofindomethacin which is unrelated to the inhibihydralazine in this group when compared with hypoxia tion of prostaglandin synthesis, meclofenamate, an alone.
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-U. lated to indomethacin, was given to a group of dogs (n = 3), and the identical protocol for the indomethacin experiment was followed. Control pulmonary artery pressure in this group was 6.0+3.4 mm Hg, and control pulmonary arteriolar resistance was 1.3 +0. 4 .9±0.9 U). To determine whether the pulmonary vasculature of dogs pretreated with cyclo-oxygenase inhibitors still maintained the ability to dilate upon exposure to a drug which was not dependent on prostaglandin synthesis for its effect, we studied the effects of the intravenous infusion of prostacyclin (PGI2), 5 ,ug/kg per min for 2 min, on the hemodynamics of three dogs pretreated with indomethacin (Fig. 4) . Hypoxic ventilation raised mean pulmonary arterial pressure to comparable levels, but prostacyclin caused a prompt reduction in mean pulmonary arterial pressure, and this effect persisted for <20 min after the infusion was discontinued. DISCUSSION There has recently been a rekindled interest in the clinical usefulness of vasodilators to treat patients with pulmonary hypertension. In addition to hydralazine, pharmacologic agents of diverse chemical structure including tolazoline (32) , isoproterenol (33) , diazoxide (34) , and phentolamine (35) useful pulmonary vasodilators. Although it is unlikely that all these drugs exert their effects on the pulmonary vasculature through a common mechanism, these observations have given investigators the opportunity to evaluate the effects of these drugs in experimental pulmonary hypertension. This knowledge could lead to our increased understanding ofthe mechanisms ofpulmonary vascular reactivity. This study demonstrates that hydralazine causes pulmonary vasodilatation in the setting of acute hypoxic vasoconstriction, and suggests that this effect may be mediated by prostaglandins.
During continuous hypoxic ventilation, the administration of hydralazine resulted in a reduction of pulmonary arterial pressure in anesthetized animals. Because cardiac output and pulmonary arterial wedge pressure were not altered, the decline in pulmonary artery pressure reflects a change in pulmonary vascular tone. A decrease in pulmonary blood volume could account for the observed pressure changes, but it is unlikely that hydralazine, an arteriolar dilator (36) , would have an effect on venous capacitance. Furthermore, the volumes of blood removed for analysis and the amount offluid infused to maintain catheter patency were always kept below 40 ml, respectively, for each study. It is also not likely that the fall in pulmonary artery pressure demonstrated resulted from the decay of the hypoxic pressor response, since this and other studies have demonstrated that continuous hypoxic ventilation in dogs produces a stable degree of pulmonary hypertension for at least 3 h (37) .
The hemodynamics during ventilation both with room air and 10% oxygen were comparable in both groups. However, hydralazine had no effect on either pulmonary artery pressure or pulmonary arteriolar resistance in the dogs that were pretreated with either indomethacin or meclofenamate. In addition to its inhibition ofprostaglandin synthetase, indomethacin has several other pharmacologic actions, but these are generally seen at doses much higher than those given in this study (26) . The observation that prostacyclin lowered pulmonary arterial pressure in the presence of indomethacin makes it unlikely that indomethacin exerts a nonspecific effect on the ability of the pulmonary vasculature to respond to vasodilators.
The precise role of prostaglandins in the regulation of the pulmonary circulation remains unclear. Bergofsky (41) has suggested that other vasoactive compounds, such as histamine, may be mediators ofhypoxic pulmonary vasoconstriction. Other investigators have suggested that vasoconstrictor prostaglandins released as a result of the hypoxic stimulus lead to pulmonary hypertension. Kadowitz and others (8, 11, (14) (15) (16) have postulated that vasodilator prostaglandins may contribute to the maintenance ofthe normal condition ofa low pressure state in the pulmonary aterial tree. They further suggest that vasoconstriction during hypoxia may be the result ofthe inhibition of synthesis ofthese prostaglandin compounds.
Of the vasoactive prostaglandins, prostacyclin is the most potent pulmonary vasodilator (7) (8) (9) . Prostacyclin is produced in the lung (38) (39) (40) and in other organs.
It seems possible, therefore, that hydralazine lowers pulmonary artery pressure by stimulating the production of a vasodilator prostaglandin, possibly prostacyclin, either in the lung or at a distal site. Although measurements of prostaglandin metabolites in experimental preparations similar to ours are needed to confirm this hypothesis, the inhibition of the pulmonary vasodilator effects of hydralazine by indomethacin suggests that a vasodilator prostaglandin plays a crucial role in the hemodynamic responses observed with hydralazine administration.
